Henry Schein, Inc. to Post Q3 2017 Earnings of $0.90 Per Share, Barrington Research Forecasts (HSIC)
Henry Schein, Inc. (NASDAQ:HSIC) – Barrington Research increased their Q3 2017 earnings per share (EPS) estimates for Henry Schein in a research note issued to investors on Tuesday. Barrington Research analyst M. Petusky now expects that the company will earn $0.90 per share for the quarter, up from their prior estimate of $0.90.
Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, August 8th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.86 by $0.02. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The firm had revenue of $3.06 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same period last year, the firm posted $0.82 EPS. The business’s revenue was up 6.4% compared to the same quarter last year.
Other research analysts also recently issued reports about the company. UBS AG reaffirmed a “buy” rating on shares of Henry Schein in a report on Friday, September 15th. Northcoast Research raised Henry Schein from a “neutral” rating to a “buy” rating and set a $109.00 price target on the stock in a report on Monday, August 7th. Robert W. Baird set a $95.00 price target on Henry Schein and gave the company a “buy” rating in a report on Thursday, October 19th. Morgan Stanley initiated coverage on Henry Schein in a report on Thursday, September 21st. They set an “equal weight” rating and a $88.00 price target on the stock. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $89.00 price target on shares of Henry Schein in a report on Thursday, October 19th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $92.89.
Shares of Henry Schein (HSIC) opened at 82.97 on Wednesday. The stock has a market capitalization of $13.12 billion, a price-to-earnings ratio of 24.25 and a beta of 1.08. Henry Schein has a 12 month low of $73.11 and a 12 month high of $93.50. The stock’s 50 day moving average price is $82.37 and its 200 day moving average price is $87.29.
A number of institutional investors and hedge funds have recently modified their holdings of HSIC. YorkBridge Wealth Partners LLC increased its position in Henry Schein by 5.2% in the second quarter. YorkBridge Wealth Partners LLC now owns 570 shares of the company’s stock worth $104,000 after buying an additional 28 shares in the last quarter. Sun Life Financial INC increased its position in Henry Schein by 8,185.7% in the second quarter. Sun Life Financial INC now owns 580 shares of the company’s stock worth $106,000 after buying an additional 573 shares in the last quarter. Trust Co. of Vermont increased its position in Henry Schein by 56.7% in the third quarter. Trust Co. of Vermont now owns 1,702 shares of the company’s stock worth $140,000 after buying an additional 616 shares in the last quarter. Lee Financial Co purchased a new stake in Henry Schein in the second quarter worth about $161,000. Finally, Benjamin F. Edwards & Company Inc. increased its position in Henry Schein by 281.8% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 2,100 shares of the company’s stock worth $172,000 after buying an additional 1,550 shares in the last quarter. Institutional investors and hedge funds own 45.90% of the company’s stock.
In other Henry Schein news, SVP Paul Rose sold 2,126 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $172.51, for a total value of $366,756.26. Following the transaction, the senior vice president now owns 17,841 shares of the company’s stock, valued at $3,077,750.91. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.19% of the stock is currently owned by corporate insiders.
Henry Schein announced that its Board of Directors has approved a share repurchase program on Monday, September 18th that authorizes the company to repurchase $400.00 million in shares. This repurchase authorization authorizes the company to buy up to 6.3% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.